Last reviewed · How we verify

premix insulin human isophane suspension and insulin human

Université NAZI BONI · FDA-approved active Small molecule Quality 1/100

premix insulin human isophane suspension and insulin human is a Small molecule drug developed by Université NAZI BONI. It is currently FDA-approved.

At a glance

Generic namepremix insulin human isophane suspension and insulin human
SponsorUniversité NAZI BONI
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about premix insulin human isophane suspension and insulin human

What is premix insulin human isophane suspension and insulin human?

premix insulin human isophane suspension and insulin human is a Small molecule drug developed by Université NAZI BONI.

Who makes premix insulin human isophane suspension and insulin human?

premix insulin human isophane suspension and insulin human is developed and marketed by Université NAZI BONI (see full Université NAZI BONI pipeline at /company/universit-nazi-boni).

What development phase is premix insulin human isophane suspension and insulin human in?

premix insulin human isophane suspension and insulin human is FDA-approved (marketed).

Related